Drug
BMS-986278
Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
BMS-986278 is a potent lysophospholipid receptor antagonist (LPA1).
IPF Study Purpose
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis (IPF).
Find a Clinical Trial
PPF Study Purpose
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (PPF).